Moritz Rapp

Title: Moritz Rapp: Innovator in Bispecific Antigen Binding Molecules

Introduction

Moritz Rapp is a distinguished inventor based in Zurich, Switzerland. He has made significant contributions to the field of biochemistry, particularly in the development of bispecific antigen binding molecules. With a total of 3 patents to his name, Rapp's work is paving the way for advancements in targeted therapies.

Latest Patents

Rapp's latest patents include innovative bispecific antigen binding molecules. One of his notable inventions is titled "Bispecific antigen binding molecules comprising anti-FAP clone 212." This invention relates to novel bispecific antigen binding molecules that include at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) comprising FAP clone 212 or variants thereof, along with another domain capable of specific binding to CD40. The patent also covers methods for producing these molecules and their applications.

Another significant patent is "Bispecific antigen binding molecules capable of specific binding to CD40 and to FAP." This invention similarly involves bispecific antigen binding molecules that include one domain specific to CD40 and another that binds to a target cell antigen, particularly Fibroblast Activation Protein (FAP). This patent also details methods for producing and utilizing these molecules.

Career Highlights

Moritz Rapp is currently associated with Hoffmann-La Roche Inc., a leading company in the pharmaceutical and biotechnology sector. His work at the company focuses on developing innovative solutions that address critical health challenges. Rapp's expertise in bispecific antibodies positions him as a key player in the advancement of targeted therapies.

Collaborations

Rapp collaborates with notable colleagues, including Peter Bruenker and Harald Duerr. Their combined efforts contribute to the innovative research and development of new therapeutic approaches in the field.

Conclusion

Moritz Rapp's contributions to the field of bispecific antigen binding molecules highlight his role as a leading inventor in biochemistry. His patents reflect a commitment to advancing medical science and improving patient outcomes.